case_images: PMC2933906_01
case_images: Patient screening MR images. (a) Axial T2-weighted image showing a heterogeneous fibroid, hyper intense relative to the uterine wall. (b) Contrast enhanced Axial T1-weighted screening MR image, showing enhancement of the fibroid.
case_images: OGI2010-834275.001.jpg
case_images: PMC2933906_01_OGI2010-834275.001.jpg
case_images: fig1
case_images: Intensity of the fibroid relative to the uterine wall was hyperintense on T2WIs, and its texture was very heterogeneous (Figure 1). TE 2.3 ms, matrix 256x115, thickness 3 mm, spacing 0.6 mm, FOV 30 cm) (Figure 2). T1-weighted axial fat-saturation images were taken 240 seconds after the injection (TR 594 ms, TE 11 ms, matrix 256x144, thickness 5 mm, spacing 1 mm, FOV 30 cm) (Figure 1). The images show low enhancement in the fibroid during the 120 seconds after the injection, despite high enhancement on the 240-second delayed scan.
case_images: Contrast-enhanced sagittal T1-weighted screening MR dynamic images acquired at 30, 60, and 90 seconds post contrast injection (from left to right). Fibroid shows lower enhancement than the myometrium in the first 2 minutes postinjection.
case_images: OGI2010-834275.002.jpg
case_images: PMC2933906_01_OGI2010-834275.002.jpg
case_images: fig2
case_images: TE 2.3 ms, matrix 256x115, thickness 3 mm, spacing 0.6 mm, FOV 30 cm) (Figure 2). T1-weighted axial fat-saturation images were taken 240 seconds after the injection (TR 594 ms, TE 11 ms, matrix 256x144, thickness 5 mm, spacing 1 mm, FOV 30 cm) (Figure 1). The images show low enhancement in the fibroid during the 120 seconds after the injection, despite high enhancement on the 240-second delayed scan.
case_images: Contrast-enhanced axial T1-weighted MR image after treatment, showing nonperfused volume of 60%.
case_images: OGI2010-834275.003.jpg
case_images: PMC2933906_01_OGI2010-834275.003.jpg
case_images: fig3
case_images: C. Contrast-enhanced T1WIs were acquired posttreatment, showing that 335 cc (60%) of the fibroid was nonenhancing (Figure 3).